Mozart Therapeutics Raises $25 Million in Expanded Series A Financing to Support Clinical Development of First-in-Class CD8 Treg Modulators for the Treatment of Autoimmune Diseases

Mozart is developing a portfolio of CD8 Treg Modulators including MTX-101, a bispecifc autoimmune checkpoint inhibitor, for the treatment of autoimmune diseases. The company anticipates filing an investigational new drug and initiating a Phase I clinical trial for MTX-101 in early 2024.